A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis

International Journal for Parasitology

Volumn 42, Issue 5, 2012, Pages 429-435

  Gupta, Reema ^a   Kushawaha, Pramod K ^a   Tripathi, Chandra Dev Pati ^a   Sundar, Shyam ^b   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cured Leishmania hamsters; Cured Leishmania patients and endemic contacts; Immunogenicity; Leishmania donovani; Methionine aminopeptidase; Prophylactic potential; Recombinant p45; T cell response

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; MESSENGER RNA; METHIONYL AMINOPEPTIDASE; RECOMBINANT LEISHMANIA DONOVANI P45 VACCINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNITY; LEISHMANIASIS; PARASITE; PROTEOMICS; RECOMBINATION; RODENT; VACCINE;

ARTICLE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; GENE EXPRESSION; HAMSTER; HUMAN; IMMUNOSTIMULATION; INFECTION PREVENTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; SURVIVAL TIME; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AMINOPEPTIDASES; ANIMALS; CHILD; CHILD, PRESCHOOL; CRICETINAE; CYTOKINES; DNA, PROTOZOAN; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; MESOCRICETUS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; TH1 CELLS; VACCINES, SYNTHETIC;

CRICETINAE; LEISHMANIA DONOVANI;

EID: 84861229658     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.02.013     Document Type: Article

References (23)

1. Bhowmick S., Mazumdar T., Ali N. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 2009, 77:1514-1523.
2. Carvalho E.M., Bacellar O., Brownell C., Regis T., Coffman R.L., Reed S.G. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 1994, 152:5949-5956.
3. Costa S.R., D'Oliveira A., Bacellar O., Carvalho E.M. T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. Mem. Inst. Oswaldo Cruz 1999, 94:367-370.
4. Garg R., Gupta S.K., Tripathi P., Naik S., Sundar S., Dube A. Immunostimulatory cellular responses of cured Leishmania infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 2005, 140:149-156.
5. Gupta S.K., Sisodia B.S., Sinha S., Hajela K., Naik S., Shasany A.K., Dube A. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 2007, 7:816-823.
6. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 1993, 177:1505-1509.
7. Holaday B.J., Pompeu M.M., Jeronimo S., Texeira M.J., Sousa Ade A., Vasconcelos A.W., Pearson R.D., Abrams J.S., Locksley R.M. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J. Clin. Invest. 1993, 92:2626-2632.
8. Khabiri A.R., Bagheri F., Assmar M. Leishmania major: species specific delayed hypersensitivity reaction induced by exogenous secreted antigen in the guinea pig. Exp. Parasitol. 2006, 112:184-186.
9. Khabiri A.R., Bagheri F., Assmar M. Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs. Parasitol. Res. 2007, 100:629-632.
10. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., Ibrahim M.E., Kamil A.A., Elsheikh M., Babiker A., Modabber F. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
11. Kumari S., Samant M., Khare P., Sundar S., Sinha S., Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa. Vaccine 2008, 26:4813-4818.
12. Kumari S., Samant M., Misra P., Khare P., Sisodia B., Shasany A.K., Dube A. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine 2008, 26:5700-5711.
13. Kushawaha P.K., Gupta R., Sundar S., Sahasrabuddhe A.A., Dube A. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-gamma and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J. Immunol. 2011, 187:6417-6427.
14. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
15. Melby P.C., Chandrasekar B., Zhao W., Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 2001, 166:1912-1920.
16. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C., Naik S. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001, 19:3485-3492.
17. Nozaki Y., Hasegawa Y., Ichiyama S., Nakashima I., Shimokata K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect. Immun. 1997, 65:3644-3647.
18. Probst P., Stromberg E., Ghalib H.W., Mozel M., Badaro R., Reed S.G., Webb J.R. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J. Immunol. 2001, 166:498-505.
19. Samant M., Gupta R., Kumari S., Misra P., Khare P., Kushawaha P.K., Sahasrabuddhe A.A., Dube A. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-Type immunoprotective response against experimental visceral leishmaniasis. J. Immunol. 2009, 183:470-479.
20. Sassi A., Louzir H., Ben Salah A., Mokni M., Ben Osman A., Dellagi K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin. Exp. Immunol. 1999, 116:127-132.
21. Singh N., Gupta R., Jaiswal A.K., Sundar S., Dube A. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J. Antimicrob. Chemother. 2009, 64(2):370-374.
22. Tripathi P., Ray S., Sunder S., Dube A., Naik S. Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals. Clin. Exp. Immunol. 2006, 143:380-388.
23. Warren H.S., Vogel F.R., Chedid L.A. Current status of immunological adjuvants. Annu. Rev. Immunol. 1986, 4:369-388.